Who
Heather A. Berger
Director
Company insider
Files Form 4 as: Director, Design Therapeutics; Director, Entasis Therapeutics Holdings.
In numbers
- Trades disclosed
- 21
- Buys
- 1
- Sells
- 0
- Bought
- $4,862
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 18 Jan 2019
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 25 Mar 2024filed 25 Mar 2024 | DSGN Design TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,8621,300 at $3.74 | filing |
| 31 May 2023filed 2 Jun 2023 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jul 2022filed 11 Jul 2022 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code J | —17,307 at $0.00 | filing |
| 11 Jul 2022filed 11 Jul 2022 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code J | —11,000 at $0.00 | filing |
| 11 Jul 2022filed 11 Jul 2022 | Entasis Therapeutics Holdings | SEC FORM 4 Code D | $61K27,500 at $2.20 | filing |
| 7 Jul 2022filed 11 Jul 2022 | Entasis Therapeutics Holdings | SEC FORM 4 Code U | $48K22,000 at $2.20 | filing |
| 15 Jun 2022filed 16 Jun 2022 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 18 Jan 2022filed 19 Jan 2022 | Entasis Therapeutics Holdings | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 16 Jul 2021filed 15 Feb 2022 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 16 Jul 2021filed 15 Feb 2022 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —11,538 | filing |
| 16 Jul 2021filed 15 Feb 2022 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —7,500 | filing |
| 16 Jul 2021filed 15 Feb 2022 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —5,769 | filing |
| 15 Jun 2021filed 16 Jun 2021 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Apr 2021filed 2 Apr 2021 | Entasis Therapeutics Holdings | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 10 Jun 2020filed 6 Oct 2020 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 19 Jun 2019filed 21 Jun 2019 | Entasis Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.